Investment
Led SonoThera's oversubscribed $125M Series B for ultrasound-mediated nonviral genetic medicines; Rajul Jain joined the board.
SonoThera
JUN 10, 2026
Every public signal F4 has attached to this firm, with sources and cross-entity links.
SonoThera
Candid Therapeutics
Poplar Therapeutics
Poplar Therapeutics
Fourth major portfolio acquisition of 2025
Halda Therapeutics
Capstan Therapeutics
Matt Cohen and Brian Goodman join as Managing Directors